This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula I



I

in which

R is H, X, A, X-CO- or A-CO-,

R^1 is H, =O, Hal, X, A, OH, OA, A-COO-, A-CONH-, A-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, -$O(CH_2)_m$COOH or -$O(CH_2)_m$OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, 4*H*-1,4-oxazin-4-yl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl or pyrazinyl,

optionally mono- or disubstituted by Hal, OA, OH, COOA and/or A, or

$CONR^4R^5$,

R^2 and R^3	together are alternatively -CH=CH-NH- or $-CH_2-CH_2-NH$, where one H atom may be replaced by A-CO- or A-O-CO-,
R^4 and R^5,	independently of one another, are H or A, or
R^4 and R^5	together are alternatively an alkylene chain having 3, 4 or 5 carbon atoms, which may also be substituted by A, Hal, OA and/or carbonyl oxygen (=CO),
X	is aryl, arylalkyl, Het or Het-alkyl,
aryl	is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, $-CH_2-COOH$ or $-OCH_2-COOH$,
Het	is a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, benzyl, cycloalkyl, OH, NH_2, $NHCONH_2$, NO_2, CN, $-CH_2-COOH$, $-CH_2-CONH_2$, NHCOA, NR^3SO_2A, CHO, SO_2NH_2, SO_2A and/or carbonyl oxygen,
A	is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
Hal	is F, Cl, Br or I,
m	is 1, 2, 3, 4, 5 or 6,
n	is 0, 1, 2, 3, 4 , 5 or 6,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 2. **(Previously Presented)** Compounds according to Claim 1, in which

R	is H or A,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 3. **(Canceled)**

Claim 4. **(Canceled)**

Claim 5. **(Currently Amended)** Compounds according to Claim 1, in which

R is H, X, A, X-CO- or A-CO-,

R^1 is H, =O, Hal, X, A, OH, OA, A-COO-, A-CONH-, A-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, -O$(CH_2)_m$COOH or -O$(CH_2)_m$OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl or pyrazinyl,

optionally mono- or disubstituted by Hal, OA, OH, COOA and/or A,

or

$CONR^4R^5$,

R^4 and R^5, independently of one another, are H or A, or

R^4 and R^5 together are alternatively an alkylene chain having 3, 4 or 5 carbon atoms,

X is aryl, arylalkyl, Het or Het-alkyl,

aryl is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, $-CH_2-COOH$ or $-OCH_2-COOH$,

Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, benzyl, cycloalkyl, OH, NH_2, $NHCONH_2$, NO_2, CN, $-CH_2-COOH$, $-CH_2-CONH_2$, NHCOA, NR^3SO_2A, CHO, SO_2NH_2, SO_2A and/or carbonyl oxygen,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which, in addition, 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 6. **(Previously Presented)** Compounds according to Claim 1, in which

R is H or A,

R^1 is H, OH, OA, O-allyl, O-propargyl, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, $-O(CH_2)_mCOOH$ or $-O(CH_2)_mOA$,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxopiperazin-1-yl, 3-oxo-2*H*-pyridazin-2-yl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl or pyrazinyl,

optionally mono- or disubstituted by Hal, OA, OH, COOA and/or A, or $CONR^4R^5$,

R^4 and R^5 together are an alkylene chain having 3, 4 or 5 carbon atoms,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in

which, in addition, 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

or ~~and~~ pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 7. **(Previously Presented)** Compounds according to C1aim 1 in which

R is H, X, A, X-CO- or A-CO-,

R^1 is H, =O, Hal, X, A, OH, OA, A-COO-, A-CONH-, A-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, -O$(CH_2)_m$COOH or -O$(CH_2)_m$OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl,

X is aryl, arylalkyl, Het or Het-alkyl,

aryl is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, -CH_2-COOH or -OCH_2-COOH,

Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, benzyl,

cycloalkyl, OH, NH_2, $NHCONH_2$, NO_2, CN, $-CH_2-COOH$, $-CH_2-CONH_2$, NHCOA, NR^3SO_2A, CHO, SO_2NH_2, SO_2A and/or carbonyl oxygen,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which, in addition, 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 8. **(Previously Presented)** Compounds according to Claim 1, in which

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 9. **(Previously Presented)** Compounds according to Claim 1, in which

R^1 is H, OH, OA, O-allyl, O-propargyl, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, $-O(CH_2)_mCOOH$ or $-O(CH_2)_mOA$,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 10. **(Previously Presented)** Compounds according to Claim 1, in which

A is unbranched or branched alkyl having 1-6 carbon atoms,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 11. **(Previously Presented)** Compounds according to Claim 1, in which

R is H or A,

R^1 is H, OH, OA, O-allyl, O-propargyl, $OCH_2CH(OH)CH_2OH$, A-O-CO-

$(CH_2)_m$-O-, -O$(CH_2)_m$COOH or -O$(CH_2)_m$OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,

optionally monosubstituted by A, OH or COOA,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which, in addition, 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 12. (Previously Presented) Compounds according to Claim 1

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-1*H*-pyrazin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxopiperidin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-fluor-4-(2-oxo-2*H*-pyridin-1-yl)-phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2S,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxopiperidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(2-oxopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[1-acetyl-2,3-dihydro-1*H*-indol-5-yl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-ethoxycarbonyl-1*H*-indol-5-yl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methoxy-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-propargyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-propargyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-methyl-2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-propargyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(5-methyl-2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-methoxycarbonyl-4-hydroxypyrrolidin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-methyl-2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2S,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-methyl-2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(6-methyl-3-oxo-2*H*-pyridazin-2-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

or pharmaceutically acceptable salts, or stereoisomers or mixtures thereof in all ratios.

Claim 13. (Previously Presented) Process for the preparation of

compounds of the formula I according to Claim1 or pharmaceutically acceptable salts or stereoisomers thereof, comprising reacting

a) a compound of the formula II



II

in which R is as defined in Claim 1,

is reacted with a chloroformate compound to give a carbamate compound intermediate,

and subsequently reacting said intermediate with a compound of the formula III



III

in which

R^1, R^2 and R^3 are as defined in Claim 1,

or

b) reacting a compound of the formula III with a compound of the formula IV



IV

in which

R is as defined in Claim 1,

or

c) reacting a compound of the formula V



V,

in which R^2 and R^3 are as defined in Claim 1,

with a compound of the formula VI



VI

in which
L is Cl, Br, I or a free or reactively functionally modified OH group, and
R and R^1 are as defined in Claim 1,

and/or converting a base or acid of the formula I is converted into one of its salts.

Claim 14. (Canceled)

Claim 15. (Canceled)

Claim 16. (Previously Presented) Medicaments comprising at least one

compound of the formula I according to Claim 1, and/or pharmaceutically acceptable, salts, stereoisomers or mixtures thereof in all ratios, and, optionally, excipients and/or adjuvants.

Claim 17. (Canceled)

Claim 18. (Currently Amended) A method for the treatment of thromboses, myocardial infarction, arteriosclerosis, apoplexia, angina pectoris, restenosis after angioplasty, or claudicatio intermittens, ~~migraine, tinnitus, tumours, tumour diseases and/or tumour metastases,~~ comprising administering a compound according to Claim 1, ~~in~~or a salt thereof, or stereoisomer or mixture thereof~~, and optionally a further medicament active ingredient,~~ to a host in need thereof.

Claim 19. (Canceled)

Claim 20. (Canceled)

Claim 21. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 1, a salt, stereoisomer or mixture thereof, and a pharmaceutically acceptable carrier.

Claim 22. (New) A method according to claim 18, wherein the compound is administered with tissue plasminogen activator, streptokinase, urokinase, asprin or blood platelet glycoprotein receptor IIb/IIIb antagonists.